Treatments

Vigil Immunotherapy and PARP 7 Treatments for Patients with Ovarian Cancer

Vigil Immunotherapy and PARP 7 Treatments for Patients with Ovarian Cancer

Vigil immunotherapy is possible for women with recurrent ovarian cancer and PARP 7 may impact ovarian cancer survival, according to two studies presented in New Orleans.

Allergic response in patients with chronic rhinosinusitis and nasal polyposis

Allergic response in patients with chronic rhinosinusitis and nasal polyposis

Researchers assessed the use of dupilumab in adults with chronic rhinosinusitis and nasal polyps who did not respond to treatment with intranasal corticosteroids.

Early dermatology consultation linked to improved diagnostic accuracy and care in cellulitis

Among patients admitted to the hospital for a provisional diagnosis of cellulitis, early dermatologic consultation was associated with improved recognition of pseudo-cellulitis, decreased antibiotic use, and earlier discharge.

Ovarian cancer patients may benefit from added hyperthermic intraperitoneal chemotherapy

Ovarian cancer patients may benefit from added hyperthermic intraperitoneal chemotherapy

The addition of HIPEC resulted in longer recurrence-free and overall survival among patients with ovarian cancer.

Glucocorticoid treatment ineffective for reducing sepsis-related mortality

Glucocorticoid treatment ineffective for reducing sepsis-related mortality

By

Hydrocortisone treatment does not effectively reduce mortality in sepsis.

Novel device may ease symptoms of tinnitus

Novel device may ease symptoms of tinnitus

By

Bimodal auditory-somatosensory treatment is noninvasive and showed no side effects.

FDA approves new hemophilia A drug with factor VIII inhibitors

FDA approves new hemophilia A drug with factor VIII inhibitors

New FDA-approved prophylactic treatment decreases bleeding episodes hemophilia A patients with factor VIII inhibitors.

Sign Up for Free e-newsletters